The future of healthcare depends on a better-connected community. In the Future of Drug Discovery (FODD) series, we bring innovators together from academia and industry to forge new neural paths in our collective brain. Our hope is to catalyse interactions to form the next-generation treatments.
Site
RSS
Apple
Données mises à jour le 02/10/2026
Classements récents
Dernières positions dans les classements Apple Podcasts et Spotify.
Liens partagés entre épisodes et podcasts
Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.
AI Statistical Programming for FDA Submissions - Louise Liu - #18
Saison 1 · Épisode 18
mercredi 20 mai 2026 • Durée 25:57
In this episode of Future of Drug Discovery, we speak with Louise Liu, Founder and CEO of Hill Research.
The statistical programming behind an FDA submission is one of the slower steps in clinical development. Eight programmers, six months and eight million dollars is roughly what it takes to produce the data package for a single Phase 3 trial.
Hill Research is doing that work with one person, in 90 minutes, with the help of generative AI.
In this conversation, we get into how the technology works, what the FDA thinks about the use of AI in submissions, the accountability question pharma executives are asking, and what the next decade of clinical development could look like if the rest of the pipeline catches up.
Be sure to like, rate and review the podcast if you enjoyed this episode!
Rahmad's Previous and Existing Team: Victor Greiff (GreiffLab). Paolo Marcatili, Ludovica Beltrame, Rasmus Høiberg-Nielsen (Antibody Design at Novo Nordisk).
"And a big shout out to budding antibody designers (scientists) everywhere especially from my home country Indonesia!' - Rahmad.
Be sure to like, rate and review the podcast if you enjoyed this episode!
Visit our website:
LinkedIn:
X:
Paul Essery and Murat Tunaboylu - Founding an AI Drug Discovery Start-Up (FODD #16)
Inorganic Chemistry at the Frontier of Immunotherapy - Björn Schimmöller - #15
Saison 1 · Épisode 15
mercredi 17 janvier 2024 • Durée 22:02
In this episode, we speak with Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.
AI, Automation and Drug Discovery - Ashwini Ghogare - #14
Saison 1 · Épisode 15
lundi 11 décembre 2023 • Durée 26:04
In this episode, we speak with Ashwini Ghogare, Head of Artificial Intelligence and Automation in Drug Discovery at MilliporeSigma, the Global Science and Technology Group at Merck.
Unleashing the Power of Computational Biology - Ming 'Tommy' Tang - #13
Saison 1 · Épisode 13
vendredi 20 octobre 2023 • Durée 33:43
In this talk, Murat speaks withMing (Tommy) Tang, Director of Computational Biology at Immunitas Therapeutics, an immuno-oncology start-up developing novel therapeutics for patients with cancer.
Tommy is a strong leader and communicator in the field of computational biology. He has dedicated his life's work to accelerating cancer research, with prominent expertise in analysing large-scale bulk sequencing data, single-cell and spatial transcriptomic data and epigenetic data.
Outside of his career at Immunitas, Tommy is a brilliant science communicator and teacher, with various educational streams, including Twitter, a blog, a GitHubrepository, a YouTube channel, a newsletter, as well as authoring his own book, 'From Cell Line To Command Line'. He is passionate about teaching biologists the computational skills essential for modern science.
You will learn:
How to stay ahead of the curve: developing the data analysis and bioinformatics skills essential to modern research.
Digital Foundations For Rapid Healthcare Advancement - Nikhil Reddy Podduturi - #12
Nikhil co-leads the laboratory and data science chapters at the BI X headquarters in Germany and China. The team at BI X is pioneering digital innovations to improve the lives of patients and animals. The current technologies developed by BI X include PetPro Connect, Farmera, and Pathological Speech Processing, with impacts spanning multiple healthcare fields.
Nikhil's current work involves developing new tools to accelerate drug discovery with advanced genetic sequencing technologies, designing new in silico systems to identify indications for drugs, as well as incorporating AI and ML technologies across BI X's digital health platforms.
You will learn:
How the BI X team was founded.
How BI X is using a data-driven approach to advance drug discovery and healthcare.
Regulatory steps involved in approving a digital health product.
In this talk, Murat speaks withAbhishek Pandey, Principle Research Scientist and Pharma Discovery Group Lead at AbbVie.
Abhishek currently leads RAIDERS, a Pharma Discovery group integrating machine learning across all of AbbVie's working groups to augment drug discovery capabilities. Abhishek's groups work spans cheminformatics, imaging research, multi-omics, as well as the computation behind many of AbbVie's current partnerships and collaborations.
We'll be exploring how the machine learning group is transforming the processes across multiple working groups at the pharmaceutical giant, AbbVie. We'll also be unravelling the story of how Abhishek began his pioneering work at AbbVie.
You will learn:
About Abhishek's strategy for bridging chemistry, biology and computer science expertise to integrate machine learning across AbbVie's pharma discovery processes.
About Abhishek's vision for the future of drug discovery, as we explore the pressing needs of the pharmaceutical industry from both a technical and social standpoint.
About Abhishek:
Abhishek started his career as a software engineer at Toshiba. Following this, Abhishek began his PhD in medical engineering and image processing at the University of Arizona. This led Abhishek to become a core member of the precision medicine AI team at Tempus, developing ways to improve cancer imaging pipelines to help oncologists detect cancers more efficiently. Abhishek then joined AbbVie, where he founded the machine learning / deep learning team - the influence of which has expanded across the entire company.
Reimagining Therapeutic Antibodies Using AI - Tzvika Hartman - #10
Saison 1 · Épisode 10
mardi 18 avril 2023 • Durée 23:30
In this talk, Murat speaks withTzvika Hartman, Senior Vice President of Computation at Biolojic Design, a company curating AI-designed antibodies focused on autoimmune diseases and immuno-oncology applications.
Biolojic uses machine learning to design 'programmable' antibodies with more precise molecular effects. These antibodies work dynamically with their environment, both temporally and spatially, opening avenues for new ways to alter biology. Their lead candidate, AU-007, pioneered by spin-out company Aulos Bioscience, is being advanced through Phase II clinical studies in solid tumour cancers.
Don't miss this exciting opportunity to learn about the technology and strategies at Biolojic Design directly from Tzvika. Furthermore, we'll be exploring Tzvika's fascinating and eventful career.
About Tzvika:
Tzvika has more than 30 years of experience in computer science research and software engineering. He worked at Google, Tel Aviv for 8 years as a software engineer, before founding Google's Health group in Tel Aviv, leading various projects over 5 years. Tzvika now leads the computational advancements at Biolojic Design. Things mentioned:
Machine Learning-Based Design of Antibodies Against Difficult Targets - Ben Holland - #9
Saison 1 · Épisode 9
mardi 4 avril 2023 • Durée 26:22
In this captivating podcast series, we dive deep into the world of computational antibody discovery with Ben Holland, our Co-Founder and CTO at Antiverse. Join us as we uncover the immense potential of merging computational and experimental techniques in the pursuit of revolutionary antibodies, as Ben sheds light on the strong benefits and formidable challenges encountered when targeting complex molecules such as GPCRs. With an emphasis on precision and accuracy in predicting antibody-antigen interactions, Ben shares remarkable insights and breakthroughs achieved by computational discovery techniques. Tune in and join us at the forefront of antibody discovery!
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
We'll notify you when a new event is scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
We'll notify you when a new event is scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
We'll notify you when there's a new event scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
We'll notify you when there's a new event scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
PADME (Protein And Drug Molecule interaction prEdiction), a framework based on Deep Neural Networks, to predict real-valued interaction strength between compounds and proteins.
NeurIPS Conference (Conference on Neural Information Processing Systems)
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a main focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
We'll notify you when there's a new event scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.
Never miss a future event!
We'll notify you when there's a new event scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.
Podcasts Similaires Basées sur le Contenu
Découvrez des podcasts liées à Future of Drug Discovery. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !
